NH2-terminal Pro-brain Natriuretic Peptide and Risk of Diabetes

Overview

Journal Diabetes

Specialty Endocrinology

Date 2013 Jun 5

PMID 23733199

Citations 55

Authors

Mariana Lazo

J Hunter Young

Frederick L Brancati

Josef Coresh

Seamus Whelton

Chiadi E Ndumele

Ron Hoogeveen

Christie M Ballantyne

Elizabeth Selvin

Affiliations

Soon will be listed here.

Abstract

Brain natriuretic peptide (BNP) has an established role in cardiovascular disease (CVD). However, recent animal studies suggest direct metabolic effects of BNP. To determine the association of BNP with the risk of diabetes, we conducted a prospective analysis of participants from the Atherosclerosis Risk in Communities (ARIC) study. We included 7,822 men and women without history of diabetes, CVD, or reduced kidney function at baseline. At baseline, NH2-terminal (NT)-proBNP, a cleavage product of BNP, was inversely associated with adiposity, fasting glucose, insulin, and cholesterol but positively associated with blood pressure and C-reactive protein levels. During a median follow-up of 12 years, 1,740 participants reported a new diagnosis of diabetes or medication use for diabetes. Baseline quartiles of NT-proBNP were inversely associated with diabetes risk, even after multivariable adjustment including fasting glucose. The adjusted HRs for diabetes were 1.0 (reference), 0.84 (95% CI 0.74-0.96), 0.79 (95% CI 0.68-0.90), and 0.75 (95% CI 0.64-0.87) for the 1st, 2nd, 3rd, and 4th quartiles of baseline NT-proBNP, respectively (P for trend <0.001). This inverse association was robust across sex, race, and obesity subgroups. Our results extend animal studies and support a direct and important metabolic role of BNP in humans.

Citing Articles

Sacubitril/Valsartan Combination Partially Improves Cardiac Systolic, but Not Diastolic, Function through β-AR Responsiveness in a Rat Model of Type 2 Diabetes.

Erdogan B, Yesilyurt-Dirican Z, Karaomerlioglu I, Muderrisoglu A, Sevim K, Michel M Int J Mol Sci. 2024; 25(19).

PMID: 39408945 PMC: 11476658. DOI: 10.3390/ijms251910617.

Loss of atrial natriuretic peptide signaling causes insulin resistance, mitochondrial dysfunction, and low endurance capacity.

Carper D, Lac M, Coue M, Labour A, Martens A, Banda J Sci Adv. 2024; 10(41):eadl4374.

PMID: 39383215 PMC: 11463261. DOI: 10.1126/sciadv.adl4374.

N-terminal pro-B-type natriuretic peptide levels vary by ethnicity and are associated with insulin sensitivity after gestational diabetes mellitus.

Sharma A, Birkeland K, Nermoen I, Sommer C, Qvigstad E, Lee-Odegard S Cardiovasc Diabetol. 2024; 23(1):284.

PMID: 39097697 PMC: 11298077. DOI: 10.1186/s12933-024-02349-1.

Relative B-Type Natriuretic Peptide Deficiency May Exist in Diastolic Dysfunction in Subclinical Population.

Okamoto C, Tsukamoto O, Hasegawa T, Matsuoka K, Amaki M, Kanzaki H Circ Rep. 2024; 6(5):151-160.

PMID: 38736848 PMC: 11081706. DOI: 10.1253/circrep.CR-24-0026.

Relationship between the circulating N-terminal pro B-type natriuretic peptide and the risk of carotid artery plaque in different glucose metabolic states in patients with coronary heart disease: a CSCD-TCM study in China.

Yang T, Zheng H, Pan G, Guo R, Liu F, Liu S Cardiovasc Diabetol. 2023; 22(1):299.

PMID: 37919791 PMC: 10623780. DOI: 10.1186/s12933-023-02015-y.

References

Heinisch B, Vila G, Resl M, Riedl M, Dieplinger B, Mueller T . B-type natriuretic peptide (BNP) affects the initial response to intravenous glucose: a randomised placebo-controlled cross-over study in healthy men. Diabetologia. 2011; 55(5):1400-5. DOI: 10.1007/s00125-011-2392-1. View

Sarzani R, Dessi-Fulgheri P, Paci V, Espinosa E, Rappelli A . Expression of natriuretic peptide receptors in human adipose and other tissues. J Endocrinol Invest. 1996; 19(9):581-5. DOI: 10.1007/BF03349021. View

Cataliotti A, Schirger J, Martin F, Chen H, McKie P, Boerrigter G . Oral human brain natriuretic peptide activates cyclic guanosine 3',5'-monophosphate and decreases mean arterial pressure. Circulation. 2005; 112(6):836-40. DOI: 10.1161/CIRCULATIONAHA.105.538520. View

Braunwald E . Biomarkers in heart failure. N Engl J Med. 2008; 358(20):2148-59. DOI: 10.1056/NEJMra0800239. View

Pfister R, Sharp S, Luben R, Welsh P, Barroso I, Salomaa V . Mendelian randomization study of B-type natriuretic peptide and type 2 diabetes: evidence of causal association from population studies. PLoS Med. 2011; 8(10):e1001112. PMC: 3201934. DOI: 10.1371/journal.pmed.1001112. View

Bordicchia M, Liu D, Amri E, Ailhaud G, Dessi-Fulgheri P, Zhang C . Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat thermogenic program in mouse and human adipocytes. J Clin Invest. 2012; 122(3):1022-36. PMC: 3287224. DOI: 10.1172/JCI59701. View

Das S, Drazner M, Dries D, Vega G, Stanek H, Abdullah S . Impact of body mass and body composition on circulating levels of natriuretic peptides: results from the Dallas Heart Study. Circulation. 2005; 112(14):2163-8. DOI: 10.1161/CIRCULATIONAHA.105.555573. View

Wang T . The natriuretic peptides and fat metabolism. N Engl J Med. 2012; 367(4):377-8. DOI: 10.1056/NEJMcibr1204796. View

Rubattu S, Sciarretta S, Valenti V, Stanzione R, Volpe M . Natriuretic peptides: an update on bioactivity, potential therapeutic use, and implication in cardiovascular diseases. Am J Hypertens. 2008; 21(7):733-41. DOI: 10.1038/ajh.2008.174. View

10.

Magnusson M, Jujic A, Hedblad B, Engstrom G, Persson M, Struck J . Low plasma level of atrial natriuretic peptide predicts development of diabetes: the prospective Malmo Diet and Cancer study. J Clin Endocrinol Metab. 2011; 97(2):638-45. PMC: 3275360. DOI: 10.1210/jc.2011-2425. View

11.

Wang T, Larson M, Levy D, Benjamin E, Leip E, Wilson P . Impact of obesity on plasma natriuretic peptide levels. Circulation. 2004; 109(5):594-600. DOI: 10.1161/01.CIR.0000112582.16683.EA. View

12.

Bayes-Genis A, deFilippi C, Januzzi Jr J . Understanding amino-terminal pro-B-type natriuretic peptide in obesity. Am J Cardiol. 2008; 101(3A):89-94. DOI: 10.1016/j.amjcard.2007.11.030. View

13.

Apple F, Panteghini M, Ravkilde J, Mair J, Wu A, Tate J . Quality specifications for B-type natriuretic peptide assays. Clin Chem. 2005; 51(3):486-93. DOI: 10.1373/clinchem.2004.044594. View

14.

Khan A, Cheng S, Magnusson M, Larson M, Newton-Cheh C, McCabe E . Cardiac natriuretic peptides, obesity, and insulin resistance: evidence from two community-based studies. J Clin Endocrinol Metab. 2011; 96(10):3242-9. PMC: 3200240. DOI: 10.1210/jc.2011-1182. View

15.

. The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators. Am J Epidemiol. 1989; 129(4):687-702. View

16.

de Lemos J, Lloyd-Jones D . Multiple biomarker panels for cardiovascular risk assessment. N Engl J Med. 2008; 358(20):2172-4. DOI: 10.1056/NEJMe0801721. View

17.

Kragelund C, Gronning B, Kober L, Hildebrandt P, Steffensen R . N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med. 2005; 352(7):666-75. DOI: 10.1056/NEJMoa042330. View

18.

Whittle A, Vidal-Puig A . NPs -- heart hormones that regulate brown fat?. J Clin Invest. 2012; 122(3):804-7. PMC: 3287241. DOI: 10.1172/JCI62595. View

19.

Schneider A, Pankow J, Heiss G, Selvin E . Validity and reliability of self-reported diabetes in the Atherosclerosis Risk in Communities Study. Am J Epidemiol. 2012; 176(8):738-43. PMC: 3571247. DOI: 10.1093/aje/kws156. View

20.

Levin E, Gardner D, Samson W . Natriuretic peptides. N Engl J Med. 1998; 339(5):321-8. DOI: 10.1056/NEJM199807303390507. View